In vivo studies also confirm that ceramide is targeting GAPDH in CLL, as protein isolated from tumor tissue showed an overall decrease in GAPDH expression following treatment with C6-ceramide nanoliposomes. The gene discussed is GAPDH; the disease is neoplasm.